Corrigendum to: The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design by Keith T. Flaherty, Robert Gray, Alice Chen, Shuli Li, David Patton, Stanley R. Hamilton, Paul M. Williams, Edith P. Mitchell, A. John Iafrate, Jeffrey Sklar, Lyndsay N. Harris, Lisa M. McShane, Larry V. Rubinstein, David J. Sims, Mark Routbort, Brent Coffey, Tony Fu, James A. Zwiebel, Richard F. Little, Donna Marinucci, Robert Catalano, Rick Magnan, Warren Kibbe, Carol Weil, James V. Tricoli, Brian Alexander, Shaji Kumar, Gary K. Schwartz, Funda Meric-Bernstam, Chih-Jian Lih, Worta McCaskill-Stevens, Paolo Caimi, Naoko Takebe, Vivekananda Datta, Carlos L. Arteaga, Jeffrey S. Abrams, Robert Comis, Peter J. O Dwyer, Barbara A. Conley; for the NCI-MATCH Team.
JNCI: J Natl Cancer Inst (2020); 112(10): djz245.
Dr Carlos Arteaga’s disclosures in the Notes section of this manuscript have been updated.
The original disclosures read as follows:
Dr Arteaga reports personal fees from ABBVIE, Novartis, Lilly, Sanofi, RADIUS, TAIHO Oncology, PUMA Biotechnology, Merck, H3Biomedicine, Symphogen, OrigiMed, Immunomedics, Petra Pharma, G1 Therapeutics, and Athenex; grants from Pfizer, Lilly, RADIUS, PUMA Biotechnology, BAYER, Symphogen, and TAKEDA, outside the submitted work; relationships with Provista and Y-TRAP.
This has been changed to:
Dr. Arteaga receives or has received research grants from Pfizer, Lilly and Takeda; holds minor stock options in Provista; serves or has served in an advisory role to Novartis, Merck, Lilly, Daiichi Sankyo, Taiho Oncology, OrigiMed, Puma Biotechnology, Immunomedics, AstraZeneca, Arvinas, and Sanofi; and reports scientific advisory board remuneration from the Susan G. Komen Foundation.